• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一位泌尿科医生对前列腺癌的个人观点。

A Urologist's Personal View of Prostate Cancer.

作者信息

Schellhammer Paul F

机构信息

Department of Urology, Eastern Virginia Medical School Urology of Virginia, USA.

出版信息

Turk J Urol. 2016 Sep;42(3):121-6. doi: 10.5152/tud.2016.50318.

DOI:10.5152/tud.2016.50318
PMID:27635283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5012435/
Abstract

A urologist's personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advanced prostate cancer and thoughts on the role of old and new therapies.

摘要

一位泌尿科医生对晚期前列腺癌多种手术、激素及放射/免疫治疗方案的个人经验，以及对新旧疗法作用的思考。

相似文献

1
A Urologist's Personal View of Prostate Cancer.一位泌尿科医生对前列腺癌的个人观点。
Turk J Urol. 2016 Sep;42(3):121-6. doi: 10.5152/tud.2016.50318.
2
The effect of urologist experience on choosing active surveillance for prostate cancer.泌尿科医生的经验对前列腺癌选择主动监测的影响。
World J Urol. 2015 Nov;33(11):1701-6. doi: 10.1007/s00345-015-1528-1. Epub 2015 Mar 12.
3
Managing locally advanced prostate cancer: a urologist's and a patient's perspective.局部晚期前列腺癌的管理：泌尿科医生和患者的视角
Anticancer Drugs. 2006 Mar;17(3):245-50. doi: 10.1097/00001813-200603000-00002.
4
Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View.为何靶向前列腺特异性膜抗原（PSMA）是去势抵抗性前列腺癌治疗的重要补充：泌尿外科医生的观点
J Nucl Med. 2017 Aug;58(8):1207-1209. doi: 10.2967/jnumed.117.194753. Epub 2017 May 18.
5
Urologist's Impact on Needle Core Prostate Biopsy Histopathologic Variables Within a Single Institution.单一机构中泌尿科医生对前列腺穿刺活检组织病理学变量的影响
Urology. 2016 Jun;92:70-4. doi: 10.1016/j.urology.2016.02.016. Epub 2016 Feb 23.
6
Photodynamic therapy for prostate cancer: One urologist's perspective.光动力疗法治疗前列腺癌：一位泌尿科医生的观点。
Photodiagnosis Photodyn Ther. 2007 Mar;4(1):26-30. doi: 10.1016/j.pdpdt.2006.10.002. Epub 2006 Nov 13.
7
Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view.肾细胞癌的免疫治疗。从泌尿科医生角度的批判性评估。
Urol Int. 1999;63(1):16-21. doi: 10.1159/000030413.
8
The urologist's guide to low dose-rate interstitial brachytherapy with permanent seed implants for localized prostate cancer.泌尿外科医生关于采用永久性种子植入进行低剂量率组织间近距离治疗局限性前列腺癌的指南。
BJU Int. 2007 Mar;99(3):497-501. doi: 10.1111/j.1464-410X.2006.06587.x. Epub 2006 Nov 7.
9
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.二氯化镭-223治疗转移性去势抵抗性前列腺癌：泌尿外科医生的观点
Urology. 2015 Apr;85(4):717-24. doi: 10.1016/j.urology.2014.11.031. Epub 2015 Feb 11.
10
Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view.前列腺特异性抗原（PSA）时代放疗与根治性前列腺切除术：一位泌尿科医生的观点
Semin Radiat Oncol. 1998 Apr;8(2):87-94. doi: 10.1016/s1053-4296(98)80004-0.

引用本文的文献

1
PSA screening in high-risk groups: what are the changes in benefits and harm?高危人群中的前列腺特异性抗原（PSA）筛查：益处与危害有哪些变化？
Br J Cancer. 2022 Oct;127(7):1173-1174. doi: 10.1038/s41416-022-01947-8. Epub 2022 Aug 23.
2
The resurgence of estrogens in the treatment of castration-resistant prostate cancer.雌激素在去势抵抗性前列腺癌治疗中的再度兴起。
Indian J Urol. 2019 Jul-Sep;35(3):189-196. doi: 10.4103/iju.IJU_56_19.
3
Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?局限性前列腺癌的聚焦治疗：在主动监测和确定性治疗之间是否存在“中间地带”？
Asian J Androl. 2018 Aug 31;21(1):37-44. doi: 10.4103/aja.aja_64_18.

本文引用的文献

1
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.转移性前列腺癌中的DNA修复缺陷与奥拉帕利
N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
2
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.寡转移去势抵抗性前列腺癌立体定向体部放疗后无进展生存的多中心分析。
Eur Urol. 2016 Jan;69(1):9-12. doi: 10.1016/j.eururo.2015.07.004. Epub 2015 Jul 16.
3
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
4
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.双极雄激素疗法对无症状去势抵抗性前列腺癌男性患者的疗效：一项试点临床研究的结果
Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.
5
Enzalutamide in metastatic prostate cancer before chemotherapy.恩杂鲁胺治疗化疗前转移性前列腺癌。
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
6
Gonadal steroids and body composition, strength, and sexual function in men.男性的性腺类固醇与身体组成、力量及性功能
N Engl J Med. 2013 Dec 19;369(25):2456. doi: 10.1056/NEJMc1313169.
7
Gonadal steroids and body composition, strength, and sexual function in men.男性的性腺类固醇与身体成分、力量和性功能。
N Engl J Med. 2013 Sep 12;369(11):1011-22. doi: 10.1056/NEJMoa1206168.
8
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
9
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.基于 40-55 岁时前列腺特异性抗原与长期转移风险之间关系的前列腺癌检测策略：病例对照研究。
BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023.
10
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.立体定向体部放疗治疗寡转移前列腺癌。
Front Oncol. 2013 Jan 22;2:215. doi: 10.3389/fonc.2012.00215. eCollection 2012.